The DOI matches its Crossref record; 39 of the 44 references it cites were found in a registry or an index.
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Open accessAbstract
Importance: Cerebrospinal fluid phosphorylated tau (p-tau) 181, p-tau217, and p-tau231 are associated with neuropathological outcomes, but a comparison of these p-tau isoforms in blood samples is needed. Objective: To conduct a head-to-head comparison of plasma p-tau181 and p-tau231 measured on the single-molecule array (Simoa) platform and p-tau181 and p-tau217 measured on the Meso Scale Discovery (MSD) platform on amyloid and tau positron emission tomography (PET) measures, neurodegeneration, vascular pathology, and cognitive outcomes. Design, Setting, and Participants: This study included data from the Mayo Clinic Study on Aging collected from March 1, 2015, to September 30, 2017, and analyzed between December 15, 2020, and May 17, 2021. Associations between the 4 plasma p-tau measures and dichotomous amyloid PET, metaregion of interest tau PET, and entorhinal cortex tau PET were analyzed using logistic regression models; the predictive accuracy was summarized using area under the receiver operating characteristic curve (AUROC) statistic. Of 1329 participants without dementia and with p-tau181 and p-tau217 on MSD, 200 participants with plasma p-tau181 and p-tau231 on Simoa and magnetic resonance imaging and amyloid and tau PET data at the same study visit were eligible. Main Outcomes And Measures: Primary outcomes included amyloid (greater than 1.48 standardized uptake value ratio) and tau PET, white matter hyperintensities, white matter microstructural integrity (fractional anisotropy genu of corpus callosum and hippocampal cingulum bundle), and cognition. Results: Of 200 included participants, 101 (50.5%) were male, and the median (interquartile range [IQR]) age was 79.5 (71.1-84.1) years. A total of 177 were cognitively unimpaired (CU) and 23 had mild cognitive impairment. Compared with amyloid-negative CU participants, among amyloid-positive CU participants, the median (IQR) Simoa p-tau181 measure was 49% higher (2.58 [2.00-3.72] vs 1.73 [1.45-2.13] pg/mL), MSD p-tau181 measure was 53% higher (1.22 [0.91-1.56] vs 0.80 [0.66-0.97] pg/mL), MSD p-tau217 measure was 77% higher (0.23 [0.17-0.34] vs 0.13 [0.09-0.18] pg/mL), and Simoa p-tau231 measure was 49% higher (20.21 [15.60-25.41] vs 14.27 [11.27-18.10] pg/mL). There were no differences between the p-tau species for amyloid PET and tau PET metaregions of interest. However, among CU participants, both MSD p-tau181 and MSD p-tau217 more accurately predicted abnormal entorhinal cortex tau PET than Simoa p-tau181 (MSD p-tau181: AUROC, 0.80 vs 0.70; P = .046; MSD p-tau217: AUROC, 0.81 vs 0.70; P = .04). MSD p-tau181 and p-tau217 and Simoa p-tau181, but not p-tau231, were associated with greater white matter hyperintensity volume and lower white matter microstructural integrity. Conclusions and Relevance: In this largely presymptomatic population, these results suggest subtle differences across plasma p-tau species and platforms for the prediction of amyloid and tau PET and magnetic resonance imaging measures of cerebrovascular and Alzheimer-related pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of Aβ positivity using mass spectrometry %p-tau217 in cognitively normal cohorts appears better than what has been reported when using plasma p-tau217 immunoassays, although this must be confirmed in head-to-head studies22,23,48–50.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [48]
In the citing paper
“Plasma ptau-217 has repeatedly demonstrated strong prognostic performance and generally outperforms other plasma biomarkers in predicting conversion from MCI to dementia (20,24).”
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationJack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citationRoberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 797
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationKinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B
Price, J. C., Klunk, W. E., Lopresti, B. J., Lu, X., Hoge, J. A., Ziolko, S. K., Holt, D. P., MELTZER, C. C., DeKosky, S. T., & Mathis, C. A. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600146 · Cited by 723
Cited by
Sorted by citations
Items 201–246 of 246
Fan, J., Sun, Y., Liang, B., Zhang, X., Xiao, C., & Huang, Z. (2023) · PubMed Central · doi:10.12122/j.issn.1673-4254.2023.06.11 · Cited by 1
Fluid-Based Biomarkers of Alzheimer’s Disease
Rocha, N. P., Teixeira, A. L., & de Souza, L. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-43356-6_10 · Cited by 1
Biomarkers used in Alzheimer's disease diagnosis
Mishra, S. K., Singh, R., Chang, H., Obaid, A. A., & Singh, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00013-6 · Cited by 1
Tagai, K., Tatebe, H., Matsuura, S., Zhang, H., Kokubo, N., Matsuoka, K., Endo, H., Oyama, A., Hirata, K., Shinotoh, H., et al. (2023) · medRxiv · doi:10.1101/2023.09.15.23295595 · Cited by 1
Rich, A., Oh, H., & Initiative, A. D. N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.27.635113 · Cited by 1
Baumel, J., Lutz, M., Ding, C., Capal, J., Ritter, D., Krueger, D., Salter, A., Werner, K., & Liu, A. J. (2026) · medRxiv · doi:10.64898/2026.09.09.26362677
16.MRCTにて海馬の萎縮が認められた恐怖性障害の1例(第15回日本心身医学会近畿地方会演題抄録)
上田, 文., 飯田, 順., 田原, 宏., & 井川, 玄. (1992) · 心身医学
ANA Investigates: The Future of Biomarkers in Alzheimer Disease
Schindler, S. E., Ney, D. E., Goss, A., & Rabinovici, G. D. (2022) · Annals of Neurology · doi:10.1002/ana.26437
Duan, T., Li, J., Chu, J.-Y., Li, X., Pan, S.-Y., Tan, W., Zeng, Y. J., & Hu, F. (2023) · Research Square · doi:10.21203/rs.3.rs-2619861/v1
Exploring the Intersection of Dementia and Myocardial Infarction
Goyal, A., Ekelmans, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000718
Use of Modern Classification Systems for the Complex Diagnostics of Alzheimer’s Disease
Zorkina, Y., Morozova, I., Abramova, O. V., Ochneva, A., Gankina, O. A., Andryushenko, A. V., Kurmyshev, M. V., Kostyuk, G. P., & Morozova, A. Y. (2024) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-024-01637-3
Wang, R., Jian, Z., Yu, L., & Wang, C. (2024) · Scientia Sinica Chimica · doi:10.1360/ssc-2024-0194
Fluid Markers of Tau Pathology
Khan, N., & Dage, J. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_2
Self-citationFluid and Imaging Markers of Amyloid Pathology
West, T., Meyer, M. R., Kirmess, K. M., Yarasheski, K. E., Braunstein, J. B., & Verghese, P. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_1
Rich, A., Oh, H., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251361354 · Cited by 1
Zhang, S., Wu, H., Ma, L., Li, R., Zhang, L., Liu, L., He, X., & Zhao, T. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1668512
Groot, C., Cicognola, C., Bali, D., Triana‐Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Osssenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Figshare · doi:10.6084/m9.figshare.19767974
Self-citationGuo, Z., Tian, C., Shi, Y., Song, X.-R., Yin, W., Tao, Q.-Q., Liu, J., Peng, G.-P., Wu, Z.-Y., Wang, Y.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26689169
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547387
Bali, D., Hansson, O., & Janelidze, S. (2024) · Figshare · doi:10.6084/m9.figshare.26678510
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547393
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26557766
Self-citationWilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547396
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547390
Guo, Z., Tian, C., Shi, Y., Song, X.-R., Yin, W., Tao, Q.-Q., Liu, J., Peng, G.-P., Wu, Z.-Y., Wang, Y.-J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26689172
Wilson, E. N., Young, C. B., Benitez, J. A. R., Swarovski, M. S., Feinstein, I., Vandijck, M. L. J., Guen, Y. L., Kasireddy, N. M., Shahid, M., Corso, N. K., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21547384
Bayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M. D., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17126153
Self-citationGenetic architecture of Alzheimer’s disease-related plasma biomarkersPreprint
Aaltonen, A., Palviainen, T., Heikkinen, S., Herukka, S., Hiltunen, M., Kokkola, T., Kärkkäinen, S., FinnGen, Palotie, A. V., Runz, H., et al. (2025) · medRxiv · doi:10.64898/2025.12.17.25342458
Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
Anand, T., & Kumar, A. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.01.002
Machine learning algorithms for plasma AD biomarkers implementation in two real-world cohortsPreprint
Torrigiani, E. G., Bellomo, G., Cianca, D., Nardi, G., Neri, I., Chiasserini, D., Agnello, L., Ciaccio, M., Piccoli, T., Parnetti, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8987177/v1
Xu, J., Chen, H., Wang, Y., Hu, Z., Ke, Z., Huang, L., Mo, Y., Yang, D., Mao, C., Chen, Y., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag080 · Cited by 1
Qiu, Q., Qian, W., Zhao, W., Xie, H., Cao, L., Ye, L., & Initiative, A. D. N. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261439687
Rivas‐Fernández, M. Á., Basanta-Torres, S., Lindı́n, M., Zurrón, M., Dı́az, F., Pereiro, A. X., Lojo‐Seoane, C., Rodríguez‐Pérez, A. I., Labandeira-García, J. L., & Galdo‐Álvarez, S. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70333
Patel, A., Guiler, W., Pepper, S., Kemna, R. E., Kueck, P. J., Weidling, I. W., Mayfield, H. D., John, C. S., Mudaranthakam, D. P., Wilkins, H., et al. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1748524
Prevalence of high‐risk plasma p‐tau217 levels and 5‐year transition of risk status in 70‐year‐olds
Dittrich, A., Arslan, B., Skillbäck, T. B., Rydén, L., Kvartsberg, H., Gobom, J., Blennow, K., Zetterberg, H., Kern, S., & Skoog, I. G. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71545
Self-citationChen, Y., Zhang, B., Yang, S., Wang, P., Wang, X., & He, H. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345836
Suksuphew, S., & Horkaew, P. (2026) · Intelligent Systems with Applications · doi:10.1016/j.iswa.2026.200692
Gomar, J. J., Gordon, M. L., Christen, E., Giliberto, L., Keehlisen, L., Gong, M., Hoehn, N., Morley, E., O'Neil, A., Wuelfing, D. L., et al. (2026) · medRxiv · doi:10.64898/2026.06.18.26355956
Fernández-Ceballos, M. D. L. Á., Prieto-González, J. M., & Agís‐Balboa, R. C. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01752-4
Genetic architecture of Alzheimer’s disease-related plasma biomarkers
Aaltonen, A., Palviainen, T., Heikkinen, S., Herukka, S.-K., Hiltunen, M. O., Kokkola, T., Kärkkäinen, S., Palotie, A. V., Runz, H., Julkunen, V., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.07.010
Concordance between plasma biomarkers of phosphorylated tau and tau-PET: A narrative review
van Houwelingen, A., Vernooij, M. W., Vermeiren, M. R., Ossenkoppele, R., van de Giessen, E., Seelaar, H., & Neitzel, J. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261468708
Song, J., Shi, W., Suconic, J., Hazel, K., Pottanat, G., Jones, E., Deane, T., Sharma, A., Xu, C., Oishi, K., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71828
Sánchez‐Soblechero, A., Villarejo‐Galende, A., Carreras, M. T., García, Á. B., Puertas, C., Bullido, Y. F., Vieira, A., Gundín, I., Blanco-Palmero, V. A., González‐Sánchez, M., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261487171
Plasma eMTBR‐tau243 as a disease biomarker across Alzheimer's disease clinical phenotypes
Whitwell, J. L., Bhaskaran, J. G., Satoh, R., Graff‐Radford, J., Machulda, M. M., Lowe, V. J., Mielke, M. M., Dickson, D. W., Tzeng, S., Bui, J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71898
Self-citationIntegration of neuroimaging signatures of aging and Alzheimer's with fluid biomarkers
Gonzales, M. M., Ho, N. H., Wang, D. H., Rashid, T., Brandigampala, S. R., Dong, M., Martinez, D., Charisis, S., Hohman, T. J., Seshadri, S. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71889
Beament, M., Wiltshire, K., Belder, C. R. S., Abel, E., Hart, M., Heslegrave, A. J., Lunn, M. P., Rosa-Grilo, M., Swann, O., Schott, J. M., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02180-8
Self-citation
Metadata
- Authors
- Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Eli Lilly (United States) (US)
- Cohen Veterans Bioscience (US)
- King's College London (GB)
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
- ADx Neurosciences, Ghent, Belgium
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- Mayo Clinic in Florida (US)
- Department of Neurology, Mayo Clinic, Rochester, Minnesota
- Corresponding author
- Mielke, Michelle M.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-09-01
- Volume
- 78
- Issue
- 9
- Pages
- 1108
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC8314178
- OpenAlex
- W3183927686
- Cited by
- 244
- References
- 44
- Citations by year
- 2026: 33 · 2025: 58 · 2024: 50 · 2023: 48 · 2022: 48 · 2021: 6
- FWCI
- 27.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- European Commission (860197)
- Vetenskapsrådet (2017-00915)
- National Institutes of Health
- National Institute on Aging (U01AG006786, R01AG011378, R01AG041851, R37AG011378, P30AG062677)
- National Institute of Neurological Disorders and Stroke (R01NS097495)
- H2020 European Research Council (681712)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- phosphorylated tau, plasma biomarkers, p-tau181, p-tau217, p-tau231, amyloid PET, tau PET, amyloid-beta, neurodegeneration, white matter hyperintensities, fractional anisotropy, cognitive impairment, Simoa, MSD, Alzheimer's disease, vascular pathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Nerve Degeneration, Phosphorylation, Biomarkers, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
